



## Emerging Therapies for PBC, NASH, ESLD and HCC Seminar Series 2017 - Chicago, IL

2/25/2017

This activity was created to address the professional practice gaps listed below:

- Using current best practices for the diagnosis and treatment approaches for Primary Biliary Cirrhosis (PBC).
- Identifying the warning signs of Non-Alcoholic Steatohepatitis (NASH) and are not familiar with emerging drugs that can slow disease progression.
- Applying new approaches and scientific research finding into treat End stage liver disease (ESLD).

1. Please respond regarding how much you agree or disagree that the gaps listed above were addressed.

|   | Disagree |     | Agree         |               |
|---|----------|-----|---------------|---------------|
| Participating in this educational activity changed your KNOWLEDGE in the professional practice gaps listed above. [10-3.90]                   | (0)      | (0) | (1)<br>10.00% | (9)<br>90.00% |
| Participating in this educational activity changed your COMPETENCE in the professional practice gaps listed above. [10-3.70]                  | (0)      | (0) | (3)<br>30.00% | (7)<br>70.00% |
| Do you feel participating in this educational activity will change your PERFORMANCE in the professional practice gaps listed above? [10-3.90] | (0)      | (0) | (1)<br>10.00% | (9)<br>90.00% |

2. Please elaborate on your previous answers. (5)

There are some management of patient care that I would do in my current management

I am an experienced APN with little liver transplant experience. This conference was a helpful way to expand my liver failure knowledge base.

Received latest info on the above.

good information on new therapeutic options for PBA and NASH

No protein restriction for cirrhotics

3. Please evaluate the effectiveness of the speaker(s) that presented at your event in improving your knowledge, competence and/or performance. (Poor = 1, Excellent = 4)

|  | Poor | Fair | Good          | Excellent     |
|--|------|------|---------------|---------------|
| Nancy Reau, MD, FAASLD, AGAF [10-3.90] | (0)  | (0)  | (1)<br>10.00% | (9)<br>90.00% |

Mary Rinella, MD [10-3.90]

(0) (0) (1) (9)  
10.00% 90.00%

Vickie Shah, PA-C [10-3.40]

(1) (0) (3) (6)  
10.00% 30.00% 60.00%

4. Please elaborate on your previous answers. (5)

All of the lecturers are excellent in their ability to provide information and answer all questions from the audience

All three presenters were great. Very informative and kept the discussion interesting.

Great presenters.

The speakers are very knowledgeable and presented the updates clearly & efficiently. Information was well organized and presented

5. Please identify a change that you will implement into practice as a result of attending this educational activity (new protocols, different medications, etc.) (7)

None

Vi E to treat NASH

Will offer new treatment options and increase education for my patients.

Timely referrals

trial of new medications available

No protein restriction for cirrhotics, know when to refer, how to treat hepatic encephalopathy other than with lactulose.

revised protocols

6. How certain are you that you will implement this change?

(7)

N/A (1-  
14.29%)

Very Certain (3-  
42.86%)

Certain (3-  
42.86%)

7. What topics do you want to hear more about, and what issues(s) in your practice will they address? (5)

Alcoholism and Alcoholic Hepatitis. Hepatitis B long term management

Up to date / evidence based practice changes

About other GI Issues

Acute liver failure

Updates as they develop

8. Were the patient recommendations based on acceptable practices in medicine?

(8)

Yes (8-  
100.00%)

10. Do you think the presentation was without commercial bias?

(8)

Yes (8-  
100.00%)

12. Please provide any additional comments you may have about this educational activity. (6)

Great conference

Great activity. I enjoyed the pre / pop / and post education quizzes.

Was good and helpful

Very well organized

good learning experience

none

As one of the participants of this educational activity, we want to encourage you to implement those ideas that were appropriate to your healthcare environment.

This evaluation is confidential and no individual will be identified by this office (Continuing Medical Education and Professional Development). It will only be used for quality improvement.

We look forward to seeing you at future University of Louisville events. Thank you very much.



## Emerging Therapies for PBC, NASH, ESLD and HCC Seminar Series 2017 - Washington, DC

6/24/2017

This activity was created to address the professional practice gaps listed below:

- Using current best practices for the diagnosis and treatment approaches for Primary Biliary Cirrhosis (PBC).
- Identifying the warning signs of Non-Alcoholic Steatohepatitis (NASH) and are not familiar with emerging drugs that can slow disease progression.
- Applying new approaches and scientific research finding into treat End stage liver disease (ESLD).

1. Please respond regarding how much you agree or disagree that the gaps listed above were addressed.

|  | Disagree |     | Agree         |               |
|--|----------|-----|---------------|---------------|
| Participating in this educational activity changed your KNOWLEDGE in the professional practice gaps listed above. [4-3.75]                   | (0)      | (0) | (1)<br>25.00% | (3)<br>75.00% |
| Participating in this educational activity changed your COMPETENCE in the professional practice gaps listed above. [3-3.67]                  | (0)      | (0) | (1)<br>33.33% | (2)<br>66.67% |
| Do you feel participating in this educational activity will change your PERFORMANCE in the professional practice gaps listed above? [3-3.67] | (0)      | (0) | (1)<br>33.33% | (2)<br>66.67% |

3. Please evaluate the effectiveness of the speaker(s) that presented at your event in improving your knowledge, competence and/or performance. (Poor = 1, Excellent = 4)

|   | Poor | Fair | Good          | Excellent     |
|---|------|------|---------------|---------------|
| Zobair Younossi, MD, MPH, FACG, FACP [4-4.00] | (0)  | (0)  | (0)           | (4)100%       |
| Kirti Shetty, MD, FACG [4-4.00]               | (0)  | (0)  | (0)           | (4)100%       |
| Brian Lam, MSHS, PA-C [4-3.75]                | (0)  | (0)  | (1)<br>25.00% | (3)<br>75.00% |

5. Please identify a change that you will implement into practice as a result of attending this educational activity (new protocols, different medications, etc.) (4)  
enroll in clinical trials

will use nash fibrosis score iphone app

Help patients understand the dx of NASH. Adding the needed supplements to help with NASH patients

new protocols.

6. How certain are you that you will implement this change?

(3)

Very Certain <sup>(3-</sup>  
100.00%)

7. What topics do you want to hear more about, and what issues(s) in your practice will they address? (2)

Wilson's disease. What to look for. .hemochromatosis.

NASH

8. Were the patient recommendations based on acceptable practices in medicine?

(4)

Yes <sup>(4-</sup>  
100.00%)

10. Do you think the presentation was without commercial bias?

(4)

Yes <sup>(4-</sup>  
100.00%)

12. Please provide any additional comments you may have about this educational activity. (1)

It was great! Thanks.

As one of the participants of this educational activity, we want to encourage you to implement those ideas that were appropriate to your healthcare environment.

This evaluation is confidential and no individual will be identified by this office (Continuing Medical Education and Professional Development). It will only be used for quality improvement.

We look forward to seeing you at future University of Louisville events. Thank you very much.



## Emerging Therapies for PBC, NASH, ESLD and HCC Seminar Series 2017 - Houston, TX

3/25/2017

This activity was created to address the professional practice gaps listed below:

- Using current best practices for the diagnosis and treatment approaches for Primary Biliary Cirrhosis (PBC).
- Identifying the warning signs of Non-Alcoholic Steatohepatitis (NASH) and are not familiar with emerging drugs that can slow disease progression.
- Applying new approaches and scientific research finding into treat End stage liver disease (ESLD).

1. Please respond regarding how much you agree or disagree that the gaps listed above were addressed.

|   | Disagree |     | Agree         |                |
|---|----------|-----|---------------|----------------|
| Participating in this educational activity changed your KNOWLEDGE in the professional practice gaps listed above. [12-3.92]                   | (0)      | (0) | (1)<br>8.33%  | (11)<br>91.67% |
| Participating in this educational activity changed your COMPETENCE in the professional practice gaps listed above. [11-3.82]                  | (0)      | (0) | (2)<br>18.18% | (9)<br>81.82%  |
| Do you feel participating in this educational activity will change your PERFORMANCE in the professional practice gaps listed above? [12-3.92] | (0)      | (0) | (1)<br>8.33%  | (11)<br>91.67% |

2. Please elaborate on your previous answers. (5)

New information for me was given about PBC, PSC, NAFLD and HCC. I am going to print the handouts, study them, and assimilate the information. Once done, I should have a couple of changes to make.

management of nash,pbc and pbs

I have been treating liver patients over 20 years, but I always learn something new at these meetings

Got up to date information

Excellent presentations

3. Please evaluate the effectiveness of the speaker(s) that presented at your event in improving your knowledge, competence and/or performance. (Poor = 1, Excellent = 4)

|                                      | Poor | Fair | Good         | Excellent      |
|--------------------------------------|------|------|--------------|----------------|
| Norman Sussman, MD, FAASLD [12-3.92] | (0)  | (0)  | (1)<br>8.33% | (11)<br>91.67% |

|                                   |     |     |               |                |
|-----------------------------------|-----|-----|---------------|----------------|
| John Vierling, MD, FACP [12-3.92] | (0) | (0) | (1)<br>8.33%  | (11)<br>91.67% |
| Saira Khaderi, MD, MPH [12-3.83]  | (0) | (0) | (2)<br>16.67% | (10)<br>83.33% |

4. Please elaborate on your previous answers. (3)

They were excellent.

All speakers were very up to date on topics and excellent at presenting them.

Dr Sussman went a little long, but entertaining, knowledgeable and informative

5. Please identify a change that you will implement into practice as a result of attending this educational activity (new protocols, different medications, etc.) (8)

new protocol for pbc

PBC screening tests and management of NASH

Continuing statin use

different meds

Following EGD screening protocol and stopping beta blockers in a patient with decompensated cirrhosis.

modify fibroscan screens

Will begin using obeticholic acid for patients with PBC and All Phos > 1.67 ULN

Improved clinical management

6. How certain are you that you will implement this change?

(11)

Certain <sup>(6-</sup>  
54.55%)

Maybe <sup>(1-</sup>  
9.09%)

Very Certain <sup>(4-</sup>  
36.36%)

7. What topics do you want to hear more about, and what issues(s) in your practice will they address? (9)

The new NAFLD/NASH Guidelines from AASLD when published.

polycystic liver disease

fatty liver

Any chronic liver disease

Combination therapies in u HCC

Evaluation of abnormal LFTs

Topics surrounding management of a post liver transplant patient

Updates Hepatitis B emerging treatments

Autoimmune Hepatitis management

8. Were the patient recommendations based on acceptable practices in medicine?

(11)

Yes (11-  
100.00%)

10. Do you think the presentation was without commercial bias?

(11)

Yes (10-  
90.91%)

No (1-  
9.09%)

12. Please provide any additional comments you may have about this educational activity. (5)

Overall excellent!

Very informative and interesting

Continue to notify me of CME in this region

Room was not comfortable (too cold)

Always printed material is welcome

As one of the participants of this educational activity, we want to encourage you to implement those ideas that were appropriate to your healthcare environment.

This evaluation is confidential and no individual will be identified by this office (Continuing Medical Education and Professional Development). It will only be used for quality improvement.

We look forward to seeing you at future University of Louisville events. Thank you very much.

---





## Emerging Therapies for PBC, NASH, ESLD and HCC Seminar Series 2017 - Los Angeles, CA

4/8/2017

This activity was created to address the professional practice gaps listed below:

- Using current best practices for the diagnosis and treatment approaches for Primary Biliary Cirrhosis (PBC).
- Identifying the warning signs of Non-Alcoholic Steatohepatitis (NASH) and are not familiar with emerging drugs that can slow disease progression.
- Applying new approaches and scientific research finding into treat End stage liver disease (ESLD).

1. Please respond regarding how much you agree or disagree that the gaps listed above were addressed.

|  | Disagree |     | Agree |         |
|--|----------|-----|-------|---------|
| Participating in this educational activity changed your KNOWLEDGE in the professional practice gaps listed above. [7-4.00]                   | (0)      | (0) | (0)   | (7)100% |
| Participating in this educational activity changed your COMPETENCE in the professional practice gaps listed above. [7-4.00]                  | (0)      | (0) | (0)   | (7)100% |
| Do you feel participating in this educational activity will change your PERFORMANCE in the professional practice gaps listed above? [7-4.00] | (0)      | (0) | (0)   | (7)100% |

2. Please elaborate on your previous answers. (3) gained more knowledge about cirrhosis, PBC and PSC.

I really felt like this was an excellent learning experience for me... I will go every year from now on. I would recommend it to all my co-workers  
current trends very practical

3. Please evaluate the effectiveness of the speaker(s) that presented at your event in improving your knowledge, competence and/or performance. (Poor = 1, Excellent = 4)

|                                | Poor | Fair | Good          | Excellent     |
|--------------------------------|------|------|---------------|---------------|
| Tse-Ling Fong, MD [7-3.86]     | (0)  | (0)  | (1)<br>14.29% | (6)<br>85.71% |
| Tram Tran, MD [7-4.00]         | (0)  | (0)  | (0)           | (7)100%       |
| Lucy Matthew, ACNP-BC [7-3.86] | (0)  | (0)  | (1)<br>14.29% | (6)<br>85.71% |

4. Please elaborate on your previous answers. (1)  
very experienced very articulate

5. Please identify a change that you will implement into practice as a result of attending this educational activity (new protocols, different medications, etc.) (5)

More appropriate pt education

More intensive pt education

education

Will be more cognizant of the the reasons for renal insufficiency.

6. How certain are you that you will implement this change?

(6)

Very Certain <sup>(5-</sup>  
83.33%)

Certain <sup>(1-</sup>  
16.67%)

7. What topics do you want to hear more about, and what issues(s) in your practice will they address? (4)

HCC radiology (terms)

HCC imaging... how to understand the terminology

HCC radiology terms/ understanding

HCC imaging

8. Were the patient recommendations based on acceptable practices in medicine?

(7)

Yes <sup>(7-</sup>  
100.00%)

10. Do you think the presentation was without commercial bias?

(7)

Yes <sup>(7-</sup>  
100.00%)

12. Please provide any additional comments you may have about this educational activity. (1)

excellent

As one of the participants of this educational activity, we want to encourage you to implement those ideas that were appropriate to your healthcare environment.

This evaluation is confidential and no individual will be identified by this office (Continuing Medical Education and Professional Development). It will only be used for quality improvement.

We look forward to seeing you at future University of Louisville events. Thank you very much.

---



## Emerging Therapies for PBC, NASH, ESLD and HCC Seminar Series 2017 - Louisville, KY

3/4/2017

This activity was created to address the professional practice gaps listed below:

- Using current best practices for the diagnosis and treatment approaches for Primary Biliary Cirrhosis (PBC).
- Identifying the warning signs of Non-Alcoholic Steatohepatitis (NASH) and are not familiar with emerging drugs that can slow disease progression.
- Applying new approaches and scientific research finding into treat End stage liver disease (ESLD).

1. Please respond regarding how much you agree or disagree that the gaps listed above were addressed.

|   | Disagree |     | Agree        |                |
|---|----------|-----|--------------|----------------|
| Participating in this educational activity changed your KNOWLEDGE in the professional practice gaps listed above. [21-3.95]                   | (0)      | (0) | (1)<br>4.76% | (20)<br>95.24% |
| Participating in this educational activity changed your COMPETENCE in the professional practice gaps listed above. [21-3.90]                  | (0)      | (0) | (2)<br>9.52% | (19)<br>90.48% |
| Do you feel participating in this educational activity will change your PERFORMANCE in the professional practice gaps listed above? [20-3.95] | (0)      | (0) | (1)<br>5.00% | (19)<br>95.00% |

2. Please elaborate on your previous answers. (11)  
good update and refresher

these topics are pertinent to my current job and I will be using this information to build my knowledge base.

The course was excellent. Lot of good review but also good information that I will use in my practice

provided updated evidence practice and guidance

I am new to liver service and this was an excellent resource to building my clinical skill set.

I have gained a better understanding of each of the disease processes discussed & patients who are decompensating

good program

I have a much richer knowledge base of PBC.

Gained practical knowledge that will be used for specific recommendations to NASH

patients.

I know when to call my GI physician for help wit my PBC patients

I will pay more attention to "mildly elevated" LFTs.

3. Please evaluate the effectiveness of the speaker(s) that presented at your event in improving your knowledge, competence and/or performance. (Poor = 1, Excellent = 4)

|   | Poor | Fair         | Good         | Excellent      |
|---|------|--------------|--------------|----------------|
| Craig McClain, MD [21-3.95]               | (0)  | (0)          | (1)<br>4.76% | (20)<br>95.24% |
| Matthew Cave, MD [21-3.95]                | (0)  | (0)          | (1)<br>4.76% | (20)<br>95.24% |
| Barbara Cave, MSN, APRN, FNP-BC [21-3.81] | (0)  | (1)<br>4.76% | (2)<br>9.52% | (18)<br>85.71% |

4. Please elaborate on your previous answers. (12)  
all competent and knowledgable

Dr. Smart was also excellent too.

All were excellent speakers.

All the speakers were excellent, very well run program  
good presenters

All great topics and expert speakers

Dr.'s Smart & Barve were also excellent. All shared relevant, up to date information, some of it was over my head as a clinical research nurse, but these presentations improved my understanding greatly of liver disease.

Very well organized and knowledgeable

They were all very knowledgeable in their subject and explained it thoroughly.

Engaging speakers, willing to take questions.

All excellent speakers

Speakers were excellent and engaging.

5. Please identify a change that you will implement into practice as a result of attending this educational activity (new protocols, different medications, etc.) (16)  
investigate using level of fibrosis on fibroscan to determine which cirrhotics with low platelets can do without EGD

It will help me be able to educate my patients.

Better surviellance of patients

suggest and remind patients of newer and ongoing recommended treatment options for fatty liver

More frequent ultrasounds on my liver patients with cirrhosis

screening patients and make more aggressive recommendations for tx

in review of patients referred to service I would be more alert to indications for acuity.

having an increased awareness of additional health risks that liver disease poses to patients

My assessments will be more thorough based on the information presented.

new treatments  
monitoring of PSC, PBC and nash  
Paying closer attention to my patient's labs.  
Specific exercise target levels for NASH patients.  
further management of liver disorders  
We will see NASH patients much quicker than we have in the past  
I have increased comfort in using UDCA

6. How certain are you that you will implement this change?

(19)

Certain <sup>(5-</sup>  
26.32%)

Very Certain <sup>(13-</sup>  
68.42%)

Maybe <sup>(1-</sup>  
5.26%)

7. What topics do you want to hear more about, and what issues(s) in your practice will they address? (12)

Chronic Hep B monitoring and treatment

nursing and patient education topics.

NASH and HCV

chronic hepatitis B update drug induced liver injury

When should a liver biopsy be done in patient's with unknown causes of elevated liver enzymes. What are the best drugs for Hepatitis C treatment

IBD, lean fatty liver.

NASH & NAFL disease progression so I can better explain to patients what is happening since this disease is increasing in prevalence

n/a

hepatitis C

Diagnosing and treating cirrhosis.

Drug-induced liver injury.

liver disease

8. Were the patient recommendations based on acceptable practices in medicine?

(21)

Yes <sup>(21-</sup>  
100.00%)

10. Do you think the presentation was without commercial bias?

(20)

Yes <sup>(19-</sup>  
95.00%)

No <sup>(1-</sup>  
5.00%)

12. Please provide any additional comments you may have about this educational activity. (7)

very good live CME

excellent speakers

Excellent

no additional comments

a great day of learning

Very well organized

none

As one of the participants of this educational activity, we want to encourage you to implement those ideas that were appropriate to your healthcare environment.

This evaluation is confidential and no individual will be identified by this office (Continuing Medical Education and Professional Development). It will only be used for quality improvement.

We look forward to seeing you at future University of Louisville events. Thank you very much.